BofA lowered the firm’s price target on C4 Therapeutics to $2 from $5 and keeps a Neutral rating on the shares on lower estimates pending more robust data updates. After having hosted C4’s CEO, CFO and CMO to discuss Q4 clinical readouts of two lead assets, the firm believes the data will “more likely be incremental updates rather than value inflection milestones,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CCCC: